Amantadine for fatigue in multiple sclerosis

Impact of Fatigue in Parkinson’s Disease: The Fatigue Impact Scale for Daily Use (D-FIS)

“…Amantadine has been found to be potentially useful in the management of fatigue associated to multiple sclerosis [56][57][58], but -to our knowledge -it has not been formally tested as treatment for this symptom in PD [59,60]. Although the present study was not aimed at exploring therapeutic aspects, this finding might be considered for future studies.…”

Impact of Fatigue in Parkinson’s Disease: The Fatigue Impact Scale for Daily Use (D-FIS)

“…Amantadine has been found to be potentially useful in the management of fatigue associated to multiple sclerosis [56][57][58], but -to our knowledge -it has not been formally tested as treatment for this symptom in PD [59,60]. Although the present study was not aimed at exploring therapeutic aspects, this finding might be considered for future studies.…”

Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis

“…Numerous placebo-controlled trials reported beneficial effects of amantadine in reduction of fatigue based on subjective assessments [16]. However, based on the small sample sizes of the mentioned studies and possible biases in their designs, there is no consensus on formal prescribing of this drug in MS-associated fatigue [17]. Although data regarding the role of ondansetron in reduction of fatigue is less than amantadine, ondansetron has been successfully prescribed in patients with primary biliary cirrhosis [12] and chronic hepatitis C [13].…”

Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment

“…Further specific pharmacological options comprise amantadine, modafinil, pemoline and fampridine, which demonstrated an effect in randomized, placebo-controlled trials. Amantadine has monoaminergic, cholinergic and glutaminergic effects on the CNS and is most widely used with modestly effectiveness to treat fatigue [Taus et al 2003]. Modafinil has 1-adrenergic properties and has been studied in two trials with controversial results [Stankoff et al 2005;Rammohan et al 2002].…”

Impact of Fatigue in Parkinson’s Disease: The Fatigue Impact Scale for Daily Use (D-FIS)

“…Amantadine has been found to be potentially useful in the management of fatigue associated to multiple sclerosis [56][57][58], but -to our knowledge -it has not been formally tested as treatment for this symptom in PD [59,60]. Although the present study was not aimed at exploring therapeutic aspects, this finding might be considered for future studies.…”

Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis

“…Numerous placebo-controlled trials reported beneficial effects of amantadine in reduction of fatigue based on subjective assessments [16]. However, based on the small sample sizes of the mentioned studies and possible biases in their designs, there is no consensus on formal prescribing of this drug in MS-associated fatigue [17]. Although data regarding the role of ondansetron in reduction of fatigue is less than amantadine, ondansetron has been successfully prescribed in patients with primary biliary cirrhosis [12] and chronic hepatitis C [13].…”

Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment

“…Further specific pharmacological options comprise amantadine, modafinil, pemoline and fampridine, which demonstrated an effect in randomized, placebo-controlled trials. Amantadine has monoaminergic, cholinergic and glutaminergic effects on the CNS and is most widely used with modestly effectiveness to treat fatigue [Taus et al 2003]. Modafinil has 1-adrenergic properties and has been studied in two trials with controversial results [Stankoff et al 2005;Rammohan et al 2002].…”

Impact of Fatigue in Parkinson’s Disease: The Fatigue Impact Scale for Daily Use (D-FIS)

“…Amantadine has been found to be potentially useful in the management of fatigue associated to multiple sclerosis [56][57][58], but -to our knowledge -it has not been formally tested as treatment for this symptom in PD [59,60]. Although the present study was not aimed at exploring therapeutic aspects, this finding might be considered for future studies.…”

Comparison of the effects of amantadine and ondansetron in treatment of fatigue in patients with multiple sclerosis

“…Numerous placebo-controlled trials reported beneficial effects of amantadine in reduction of fatigue based on subjective assessments [16]. However, based on the small sample sizes of the mentioned studies and possible biases in their designs, there is no consensus on formal prescribing of this drug in MS-associated fatigue [17]. Although data regarding the role of ondansetron in reduction of fatigue is less than amantadine, ondansetron has been successfully prescribed in patients with primary biliary cirrhosis [12] and chronic hepatitis C [13].…”

Review: Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment

“…Further specific pharmacological options comprise amantadine, modafinil, pemoline and fampridine, which demonstrated an effect in randomized, placebo-controlled trials. Amantadine has monoaminergic, cholinergic and glutaminergic effects on the CNS and is most widely used with modestly effectiveness to treat fatigue [Taus et al 2003]. Modafinil has 1-adrenergic properties and has been studied in two trials with controversial results [Stankoff et al 2005;Rammohan et al 2002].…”